# Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.

> **NCT02891213** · — · UNKNOWN · sponsor: **CHU de Reims** · enrollment: 150 (estimated)

## Conditions studied

- Lupus Erythematosus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02891213
- **Lead sponsor:** CHU de Reims
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2017-01
- **Final completion:** 2017-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02891213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02891213, "Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02891213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*